牛牛AI助理已提取核心訊息
Cassava Sciences, Inc. (Cassava) announced the issuance of up to 25,342,150 shares of its common stock, par value $0.001 per share, upon the exercise of warrants distributed to all holders of common stock on the record date of December 22, 2023. The warrants, issued on January 3, 2024, are transferable and expected to trade on Nasdaq under the ticker SAVAW. Each warrant entitles the holder to purchase one share of common stock at an initial exercise price of $33.00, subject to adjustments, until November 15, 2024. The exercise of the warrants is for cash only. If all warrants are exercised, Cassava would have 67,579,069 shares of common stock issued and outstanding. The company has entered into a warrant agreement with Computershare Trust Company, N.A., as the Warrant Agent. The proceeds from the exercise of the warrants are intended for general corporate purposes, including supporting ongoing clinical trials. The offering involves substantial risks, and the company advises investors to read the 'Risk Factors' section of the prospectus supplement dated January 3, 2024, before buying shares.
Cassava Sciences, Inc. (Cassava) announced the issuance of up to 25,342,150 shares of its common stock, par value $0.001 per share, upon the exercise of warrants distributed to all holders of common stock on the record date of December 22, 2023. The warrants, issued on January 3, 2024, are transferable and expected to trade on Nasdaq under the ticker SAVAW. Each warrant entitles the holder to purchase one share of common stock at an initial exercise price of $33.00, subject to adjustments, until November 15, 2024. The exercise of the warrants is for cash only. If all warrants are exercised, Cassava would have 67,579,069 shares of common stock issued and outstanding. The company has entered into a warrant agreement with Computershare Trust Company, N.A., as the Warrant Agent. The proceeds from the exercise of the warrants are intended for general corporate purposes, including supporting ongoing clinical trials. The offering involves substantial risks, and the company advises investors to read the 'Risk Factors' section of the prospectus supplement dated January 3, 2024, before buying shares.
木薯科學公司（Cassava）宣佈，在2023年12月22日創紀錄的日期行使分配給所有普通股持有人的認股權證後，將發行最多25,342,150股普通股，面值每股0.001美元。這些認股權證於2024年1月3日發行，可轉讓，預計將在納斯達克上市，股票代碼爲SAVAW。每份認股權證使持有人有權在2024年11月15日之前以33.00美元的初始行使價購買一股普通股，但須進行調整。認股權證的行使僅限現金。如果行使所有認股權證，Cassava將發行和流通67,579,069股普通股。該公司已與作爲認股權證代理人的北卡羅來納州Computershare信託公司簽訂了認股權證協議。行使認股權證的收益用於一般公司用途，包括支持正在進行的臨床試驗。此次發行涉及重大風險，該公司建議投資者在購買股票之前閱讀2024年1月3日招股說明書補充文件中的 “風險因素” 部分。
木薯科學公司（Cassava）宣佈，在2023年12月22日創紀錄的日期行使分配給所有普通股持有人的認股權證後，將發行最多25,342,150股普通股，面值每股0.001美元。這些認股權證於2024年1月3日發行，可轉讓，預計將在納斯達克上市，股票代碼爲SAVAW。每份認股權證使持有人有權在2024年11月15日之前以33.00美元的初始行使價購買一股普通股，但須進行調整。認股權證的行使僅限現金。如果行使所有認股權證，Cassava將發行和流通67,579,069股普通股。該公司已與作爲認股權證代理人的北卡羅來納州Computershare信託公司簽訂了認股權證協議。行使認股權證的收益用於一般公司用途，包括支持正在進行的臨床試驗。此次發行涉及重大風險，該公司建議投資者在購買股票之前閱讀2024年1月3日招股說明書補充文件中的 “風險因素” 部分。
有用
沒用